Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Financing Cash Flow for the year ending December 31, 2023: USD 163.80 M

Biomea Fusion Inc Financing Cash Flow is USD 163.80 M for the year ending December 31, 2023, a 13,120.18% change year over year. Financing Cash Flow is the net cash flow resulting from a company's financing activities, including repayment/issuance of debt, equity repurchases, dividends paid, and other financial activities.

Biomea Fusion Inc Financing Cash Flow for the year ending December 31, 2022 was USD 1.24 M, a 164.74% change year over year.
Biomea Fusion Inc Financing Cash Flow for the year ending December 31, 2021 was USD 468.00 K, a -99.16% change year over year.
Biomea Fusion Inc Financing Cash Flow for the year ending December 31, 2020 was USD 55.81 M, a 21,483.14% change year over year.
Biomea Fusion Inc Financing Cash Flow for the year ending December 31, 2019 was USD -261.00 K.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends